MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences, Inc. MBX
$54.06
▲ +5.28%
(+$2.71)
Open
$52.57
Prev Close
$51.35
Day Range
$51.96 – $54.86
52W Range
$21.90 – $72.64
Market Cap
$2.47B
Beta
1.61
EPS (TTM)
$-2.41
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-09-13 |
| Shares Out. | 48,160,000 |
| Website | mbxbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 63 |
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
MBX Biosciences, Inc. is a publicly traded company under the ticker symbol MBX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-11-01)